EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Bridging the translational gap in Alzheimer’s disease: A bibliometric and evidence-based assessment of secretome and stem cell therapeutics

Tyasno Koeshermanto, Muhammad Aditya Ferdiansyah, Raden Andi Ario Tedjo, An’nurihza Zidhan Azhara, Stefanus Erdana Putra

Archives of Gerontology and Geriatrics Plus · 2026-09 · 3 (3) · 100295

DOI: 10.1016/j.aggp.2026.100295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Gerontology and Geriatrics Plus, 2026-09. Verfasst von Tyasno Koeshermanto und 4 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alzheimer’s disease (AD) is a significant worldwide challenge where few disease-modifying treatments are available. Additionally, secretome- and stem cell-based therapeutics have emerged as potential translational strategies. However, the research landscape has not been systematically assessed.

Methods

A bibliometric analysis (2003–2025) was performed using VOSviewer and Biblioshiny from Scopus data. Research hotspots, knowledge gaps, and translational implications were summarized. Preclinical and clinical evidence were combined for context.

Results

There were 182 papers identified. Most of the funding was provided by the United States and China, reflecting different priorities for clinical translation and molecular innovation. Four themes were identified by co-occurrence analysis: (1) secretome and extracellular vesicles; (2) microglia and neuroinflammation; (3) aging and neurodegenerative diseases; and (4) neural stem cells and functional recovery. Publication output increased after 2016, with a growing trend towards the translation of regenerative and cell-free therapies.

Discussion

Secretomes and stem cell-based therapies offer compelling prospects for precision AD therapy; however, roadblocks to clinical translation remain, including standardization, delivery, and regulatory approval. Cross-disciplinary interaction and streamlined pipelines are critically required to address the translational bottleneck.

Zitieren

APA

Koeshermanto, T., Ferdiansyah, M. A., Tedjo, R. A. A., Azhara, A. Z., & Putra, S. E. (2026). Bridging the translational gap in Alzheimer’s disease: A bibliometric and evidence-based assessment of secretome and stem cell therapeutics. Archives of Gerontology and Geriatrics Plus, 3(3), 100295. https://doi.org/10.1016/j.aggp.2026.100295

Vancouver

Koeshermanto T, Ferdiansyah MA, Tedjo RAA, Azhara AZ, Putra SE. Bridging the translational gap in Alzheimer’s disease: A bibliometric and evidence-based assessment of secretome and stem cell therapeutics. Archives of Gerontology and Geriatrics Plus. 2026;3(3):100295. doi:10.1016/j.aggp.2026.100295

BibTeX
@article{Koeshermanto2026,
  author = {Koeshermanto, Tyasno and Ferdiansyah, Muhammad Aditya and Tedjo, Raden Andi Ario and Azhara, An’nurihza Zidhan and Putra, Stefanus Erdana},
  title = {Bridging the translational gap in Alzheimer’s disease: A bibliometric and evidence-based assessment of secretome and stem cell therapeutics},
  journal = {Archives of Gerontology and Geriatrics Plus},
  year = {2026},
  volume = {3},
  number = {3},
  pages = {100295},
  doi = {10.1016/j.aggp.2026.100295}
}
Kostenlos starten →